### FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)

# Endocrinologic and Metabolic Drugs Advisory Committee Meeting July 9, 2003

Holiday Inn, Versailles Ballroom, Bethesda, MD

### AGENDA

8:30 a.m.	Call to Order and Introductions	Glenn Braunstein, M.D. Chair, Endocrinologic and Metabolic Drugs Advisory Committee, EMDAC
	Conflict of Interest Statement	Dornette Spell-LeSane, M.H.A., NP-C Executive Secretary, EMDAC
8:45 a.m.	Welcome and Introductory Comments	David Orloff, M.D. Director Division of Metabolic and Endocrine Drug Products, FDA

# NDA 21-366 Crestor® (rosuvastatin calcium) tablets, AstraZeneca Pharmaceuticals, agent for iPR Pharmaceuticals, Inc.

Proposed for the indication of treatment of hypercholesterolemia and mixed dyslipidemia

#### 9:00 a.m. Sponsor Presentation

Introduction and Regulatory Overview

Clinical Development Efficacy Overview

Clinical Development Safety Overview Mark S. Eliason, M.Sc. Director, Regulatory Affairs AstraZeneca

James W. Blasetto, M.D., M.P.H. Senior Medical Director AstraZeneca

Howard G. Hutchinson, M.D. Vice President, Clinical Research AstraZeneca

## Endocrinologic and Metabolic Drugs Advisory Committee Meeting July 9, 2003 Agenda (cont.)

### Sponsor Presentation (Cont.)

	The Role of Rosuvastatin in the Treatment of Hyperlipidemia	Daniel J. Rader, M.D. Associate Professor of Medicine University of Pennsylvania
10:30 a.m.	Break	
10:45 a.m.	Questions from the Committee	
11:15 a.m.	FDA Presentation	
	Efficacy	Joy Mele, M.S. Statistical Reviewer Division of Biometrics II Office of Biostatistics, FDA
	Safety and Dosing	William Lubas, M.D. Medical Officer Division of Metabolic and Endocrine Drug Products, FDA
11:45 p.m.	Questions from the Committee	
12:30 p.m.	Lunch	
1:30 p.m.	Open Public Hearing	
2:30 p.m.	Charge to the Committee	David Orloff, M.D.
2:45 p.m.	Committee Discussions/Questions	
3:30 p.m.	Break	
3:45 p.m.	Committee Discussions/Questions/Summary	
5:00 p.m.	Adjournment	